Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 5/2015

01-10-2015 | Review Article

Understanding type 2 diabetes: from genetics to epigenetics

Published in: Acta Diabetologica | Issue 5/2015

Login to get access

Abstract

The known genetic variability (common DNA polymorphisms) does not account either for the current epidemics of type 2 diabetes or for the family transmission of this disorder. However, clinical, epidemiological and, more recently, experimental evidence indicates that environmental factors have an extraordinary impact on the natural history of type 2 diabetes. Some of these environmental hits are often shared in family groups and proved to be capable to induce epigenetic changes which alter the function of genes affecting major diabetes traits. Thus, epigenetic mechanisms may explain the environmental origin as well as the familial aggregation of type 2 diabetes much easier than common polymorphisms. In the murine model, exposure of parents to environmental hits known to cause epigenetic changes reprograms insulin sensitivity as well as beta-cell function in the progeny, indicating that certain epigenetic changes can be transgenerationally transmitted. Studies from different laboratories revealed that, in humans, lifestyle intervention modulates the epigenome and reverts environmentally induced epigenetic modifications at specific target genes. Finally, specific human epigenotypes have been identified which predict adiposity and type 2 diabetes with much greater power than any polymorphism so far identified. These epigenotypes can be recognized in easily accessible white cells from peripheral blood, indicating that, in the future, epigenetic profiling may enable effective type 2 diabetes prediction. This review discusses recent evidence from the literature supporting the immediate need for further investigation to uncover the power of epigenetics in the prediction, prevention and treatment of type 2 diabetes.
Literature
1.
Kirchner H, Osler ME, Krook A, Zierath JR (2013) Epigenetic flexibility in metabolic regulation: disease cause and prevention? Trends Cell Biol 23(5):203–209CrossRefPubMed
2.
3.
Ungaro P, Mirra P, Oriente F, Nigro C, Ciccarelli M, Vastolo V, Longo M, Perruolo G, Spinelli R, Formisano P, Miele C, Beguinot F (2012) Peroxisome proliferator-activated receptor-γ activation enhances insulin-stimulated glucose disposal by reducing ped/pea-15 gene expression in skeletal muscle cells: evidence for involvement of activator protein-1. J Biol Chem 287(51):42951–42961PubMedCentralCrossRefPubMed
4.
Ungaro P, Teperino R, Mirra P, Cassese A, Fiory F, Perruolo G, Miele C, Laakso M, Formisano P, Beguinot F (2008) Molecular cloning and characterization of the human PED/PEA-15 gene promoter reveal antagonistic regulation by hepatocyte nuclear factor 4alpha and chicken ovalbumin upstream promoter transcription factor II. J Biol Chem 283(45):30970–30979PubMedCentralCrossRefPubMed
5.
Oriente F, Fernandez Diaz LC, Miele C, Iovino S, Mori S, Diaz VM, Troncone G, Cassese A, Formisano P, Blasi F, Beguinot F (2008) Prep1 deficiency induces protection from diabetes and increased insulin sensitivity through a p160-mediated mechanism. Mol Cell Biol 28(18):5634–5645PubMedCentralCrossRefPubMed
6.
Oriente F, Iovino S, Cabaro S, Cassese A, Longobardi E, Miele C, Ungaro P, Formisano P, Blasi F, Beguinot F (2011) Prep1 controls insulin glucoregulatory function in liver by transcriptional targeting of SHP1 tyrosine phosphatase. Diabetes 60(1):138–147PubMedCentralCrossRefPubMed
7.
Oriente F, Cabaro S, Liotti A, Longo M, Parrillo L, Pagano TB, Raciti GA, Penkov D, Paciello O, Miele C, Formisano P, Blasi F, Beguinot F (2013) PREP1 deficiency downregulates hepatic lipogenesis and attenuates steatohepatitis in mice. Diabetologia 56(12):2713–2722CrossRefPubMed
8.
9.
Cooper ME, El-Osta A (2010) Epigenetics: mechanisms and implications for diabetic complications. Circ Res 107(12):1403–1413CrossRefPubMed
10.
Paneni F, Costantino S, Volpe M, Lüscher TF, Cosentino F (2013) Epigenetic signatures and vascular risk in type 2 diabetes: a clinical perspective. Atherosclerosis 230(2):191–197CrossRefPubMed
11.
Piarulli F, Sartore G, Lapolla A (2013) Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol 50(2):101–110PubMedCentralCrossRefPubMed
12.
Ng SF, Lin RC, Laybutt DR, Barres R, Owens JA, Morris MJ (2010) Chronic high-fat diet in fathers programs β-cell dysfunction in female rat offspring. Nature 467(7318):963–966CrossRefPubMed
13.
Toperoff G, Aran D, Kark JD, Rosenberg M, Dubnikov T, Nissan B, Wainstein J, Friedlander Y, Levy-Lahad E, Glaser B, Hellman A (2012) Genome-wide survey reveals predisposing diabetes type 2-related DNA methylation variations in human peripheral blood. Hum Mol Genet 21(2):371–383PubMedCentralCrossRefPubMed
14.
International Diabetes Federation (2013) IDF diabetes atlas, 6th edn. Brussels, Belgium
15.
Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G, 2010 China Noncommunicable Disease Surveillance Group (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310(9):948–959CrossRefPubMed
16.
17.
Raciti GA, Nigro C, Longo M, Parrillo L, Miele C, Formisano P, Béguinot F (2014) Personalized medicine and type 2 diabetes: lesson from epigenetics. Epigenomics 6(2):229–238CrossRefPubMed
18.
Zierath JR, Barrès RE (2011) Nutritional status affects the epigenomic profile of peripheral blood cells. Epigenomics 3(3):259–260CrossRefPubMed
19.
Bennett PH (1990) Epidemiology of diabetes mellitus. In: Rifkin H, Porte D Jr (eds) Ellenberg and Rifkin’s diabetes mellitus, 4th edn. Elsevier, New York, pp 363–370
20.
InterAct Consortium, Scott RA, Langenberg C, Sharp SJ, Franks PW, Rolandsson O, Drogan D, van der Schouw YT, Ekelund U, Kerrison ND, Ardanaz E, Arriola L, Balkau B, Barricarte A, Barroso I, Bendinelli B, Beulens JW, Boeing H, de Lauzon-Guillain B, Deloukas P, Fagherazzi G, Gonzalez C, Griffin SJ, Groop LC, Halkjaer J, Huerta JM, Kaaks R, Khaw KT, Krogh V, Nilsson PM, Norat T, Overvad K, Panico S, Rodriguez-Suarez L, Romaguera D, Romieu I, Sacerdote C, Sánchez MJ, Spijkerman AM, Teucher B, Tjonneland A, Tumino R, van der DL A, Wark PA, McCarthy MI, Riboli E, Wareham NJ (2013) The link between family history and risk of type 2 diabetes is not explained by anthropometric, lifestyle or genetic risk factors: the EPIC-InterAct study. Diabetologia 56(1):60–69CrossRef
21.
Meigs JB, Cupples LA, Wilson PW (2000) Parental transmission of type 2 diabetes: the Framingham offspring study. Diabetes 49(12):2201–2207CrossRefPubMed
22.
Klein BE, Klein R, Moss SE, Cruickshanks KJ (1996) Parental history of diabetes in a population-based study. Diabetes Care 19(8):827–830CrossRefPubMed
23.
Barnett AH, Eff C, Leslie RD, Pyke DA (1981) Diabetes in identical twins. A study of 200 pairs. Diabetologia 20(2):87–93CrossRefPubMed
24.
Knowles NG, Landchild MA, Fujimoto WY, Kahn SE (2002) Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 25(2):292–297CrossRefPubMed
25.
26.
De Jesus DF, Kulkarni RN (2014) Epigenetic modifiers of islet function and mass. Trends Endocrinol Metab 25(12):628–636CrossRefPubMed
27.
28.
Joost HG (2008) Pathogenesis, risk assessment and prevention of type 2 diabetes mellitus. Obes Facts 1(3):128–137CrossRefPubMed
29.
Vigliotta G, Miele C, Santopietro S, Portella G, Perfetti A, Maitan MA, Cassese A, Oriente F, Trencia A, Fiory F, Romano C, Tiveron C, Tatangelo L, Troncone G, Formisano P, Beguinot F (2004) Overexpression of the ped/pea-15 gene causes diabetes by impairing glucose-stimulated insulin secretion in addition to insulin action. Mol Cell Biol 24(11):5005–5015PubMedCentralCrossRefPubMed
30.
Condorelli G, Vigliotta G, Iavarone C, Caruso M, Tocchetti CG, Andreozzi F, Cafieri A, Tecce MF, Formisano P, Beguinot L, Beguinot F (1998) PED/PEA-15 gene controls glucose transport and is overexpressed in type 2 diabetes mellitus. EMBO J 17(14):3858–3866PubMedCentralCrossRefPubMed
31.
Condorelli G, Vigliotta G, Trencia A, Maitan MA, Caruso M, Miele C, Oriente F, Santopietro S, Formisano P, Beguinot F (2001) Protein kinase C (PKC)-α activation inhibits PKC-ζ and mediates the action of PED/PEA-15 on glucose transport in the L6 skeletal muscle cells. Diabetes 50(6):1244–1252CrossRefPubMed
32.
Miele C, Raciti GA, Cassese A, Romano C, Giacco F, Oriente F, Paturzo F, Andreozzi F, Zabatta A, Troncone G, Bosch F, Pujol A, Chneiweiss H, Formisano P, Beguinot F (2007) PED/PEA-15 regulates glucose-induced insulin secretion by restraining potassium channel expression in pancreatic beta-cells. Diabetes 56(3):622–633CrossRefPubMed
33.
34.
Barrès R, Yan J, Egan B, Treebak JT, Rasmussen M, Fritz T, Caidahl K, Krook A, O’Gorman DJ, Zierath JR (2012) Acute exercise remodels promoter methylation in human skeletal muscle. Cell Metab 15(3):405–411CrossRefPubMed
35.
Barres R, Kirchner H, Rasmussen M, Yan J, Kantor FR, Krook A, Näslund E, Zierath JR (2013) Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. Cell Rep 3(4):1020–1027CrossRefPubMed
36.
Rönn T, Volkov P, Davegårdh C, Dayeh T, Hall E, Olsson AH, Nilsson E, Tornberg A, Dekker Nitert M, Eriksson KF, Jones HA, Groop L, Ling C (2013) A six months exercise intervention influences the genome-wide DNA methylation pattern in human adipose tissue. PLoS Genet 9(6):e1003572PubMedCentralCrossRefPubMed
37.
Godfrey KM, Sheppard A, Gluckman PD, Lillycrop KA, Burdge GC, McLean C, Rodford J, Slater-Jefferies JL, Garratt E, Crozier SR, Emerald BS, Gale CR, Inskip HM, Cooper C, Hanson MA (2011) Epigenetic gene promoter methylation at birth is associated with child’s later adiposity. Diabetes 60(5):1528–1534PubMedCentralCrossRefPubMed
38.
Ling C, Del Guerra S, Lupi R, Rönn T, Granhall C, Luthman H, Masiello P, Marchetti P, Groop L, Del Prato S (2008) Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 51(4):615–622PubMedCentralCrossRefPubMed
39.
Barrès R, Osler ME, Yan J, Rune A, Fritz T, Caidahl K, Krook A, Zierath JR (2009) Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 10(3):189–198CrossRefPubMed
40.
Yang BT, Dayeh TA, Kirkpatrick CL, Taneera J, Kumar R, Groop L, Wollheim CB, Nitert MD, Ling C (2011) Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA(1c) levels in human pancreatic islets. Diabetologia 54(2):360–367PubMedCentralCrossRefPubMed
41.
Yang BT, Dayeh TA, Volkov PA, Kirkpatrick CL, Malmgren S, Jing X, Renström E, Wollheim CB, Nitert MD, Ling C (2012) Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol Endocrinol 26(7):1203–1212CrossRefPubMed
42.
Liu ZH, Chen LL, Deng XL, Song HJ, Liao YF, Zeng TS, Zheng J, Li HQ (2012) Methylation status of CpG sites in the MCP-1 promoter is correlated to serum MCP-1 in type 2 diabetes. J Endocrinol Invest 35(6):585–589PubMed
43.
Stepanow S, Reichwald K, Huse K, Gausmann U, Nebel A, Rosenstiel P, Wabitsch M, Fischer-Posovszky P, Platzer M (2011) Allele-specific, age-dependent and BMI-associated DNA methylation of human MCHR1. PLoS One 6(5):e17711PubMedCentralCrossRefPubMed
44.
Souren NY, Tierling S, Fryns JP, Derom C, Walter J, Zeegers MP (2011) DNA methylation variability at growth-related imprints does not contribute to overweight in monozygotic twins discordant for BMI. Obesity 19(7):1519–1522CrossRefPubMed
45.
Kuehnen P, Mischke M, Wiegand S, Sers C, Horsthemke B, Lau S, Keil T, Lee YA, Grueters A, Krude H (2012) An Alu element-associated hypermethylation variant of the POMC gene is associated with childhood obesity. PLoS Genet 8(3):e1002543PubMedCentralCrossRefPubMed
46.
Zhao J, Goldberg J, Vaccarino V (2013) Promoter methylation of serotonin transporter gene is associated with obesity measures: a monozygotic twin study. Int J Obes 37(1):140–145CrossRef
47.
Groom A, Potter C, Swan DC, Fatemifar G, Evans DM, Ring SM, Turcot V, Pearce MS, Embleton ND, Smith GD, Mathers JC, Relton CL (2012) Postnatal growth and DNA methylation are associated with differential gene expression of the TACSTD2 gene and childhood fat mass. Diabetes 61(2):391–400PubMedCentralCrossRefPubMed
48.
Relton CL, Groom A, St Pourcain B, Sayers AE, Swan DC, Embleton ND, Pearce MS, Ring SM, Northstone K, Tobias JH, Trakalo J, Ness AR, Shaheen SO, Smith GD (2012) DNA methylation patterns in cord blood DNA and body size in childhood. PLoS One 7(3):e31821PubMedCentralCrossRefPubMed
49.
Drong AW, Lindgren CM, McCarthy MI (2012) The genetic and epigenetic basis of type 2 diabetes and obesity. Clin Pharmacol Ther 92(6):707–715CrossRefPubMed
Metadata
Title
Understanding type 2 diabetes: from genetics to epigenetics
Publication date
01-10-2015
Published in
Acta Diabetologica / Issue 5/2015
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-015-0741-0

Other articles of this Issue 5/2015

Acta Diabetologica 5/2015 Go to the issue

Original Article

Clinical factors that predict remission of diabetes after different bariatric surgical procedures: interdisciplinary group of bariatric surgery of Verona (G.I.C.O.V.)

Original Article

Association study of the miRNA-binding site polymorphisms of CDKN2A/B genes with gestational diabetes mellitus susceptibility

Original Article

Advanced glycation end product (AGE)-induced hepatic stellate cell activation via autophagy contributes to hepatitis C-related fibrosis

Original Article

Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control

Short Communication

Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus

Short Communication

A1c value for diabetes diagnosis in subjects with established cardiovascular disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits